Seattle-based biotech Alpine Immune Sciences is seeking $100M in an underwritten public offering.
The company of 130 employees has grown 65 percent over the last nine months and intends to build on this trajectory with the new funding.
Alpine was founded in 2015, focusing on protein engineering, and has two drugs aimed at cancer and autoimmune and inflammatory diseases currently advancing through clinical trials.